Stock listing
Shenzhen:300347 Hangzhou Tigermed Consulting Co., Ltd. (泰格医药) 股价
Home listing (Shenzhen) of Hangzhou Tigermed Consulting Co., Ltd.
Follow Hangzhou Tigermed Consulting Co., Ltd. into a list and get an email when it puts out news.
Share price · SZSE:300347
¥44.30 CNY -1.67 (-3.6%)
Close on Nov 20, 2026
- Day range
- ¥44.20 – ¥45.84 CNYNov 20, 2026
- Volume
- 8.10M sharesNov 20, 2026
- Market cap
- ¥32.53B CNYAt the close on Nov 20, 2026 · price × 734.2M shares outstanding
- 52-week range
- ¥35.57 – ¥67.85 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥692.8M CNYMedian day 11.21M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Shenzhen:300347 · Home | ¥44.30 CNY | -1.67 (-3.6%) | 8,095,974 | ¥45.41 | ¥45.84 | ¥44.20 | ¥45.97 | Close on Nov 20, 2026 |
| HKEX:3347 | $31.80 HKD | -1.54 (-4.6%) | 824,200 | $33.30 | $33.30 | $31.38 | $33.34 | Close on Nov 20, 2026 |
| OTC:HNGZY | $4.06 USD | -0.39 (-8.8%) | 250 | $4.06 | $4.06 | $4.06 | $4.45 | Close on Nov 20, 2026 |
| Frankfurt:5HZ1 | €3.58 EUR | -0.18 (-4.8%) | — | €3.62 | €3.62 | €3.58 | €3.76 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:300347 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥44.30 | -1.67 | -3.6% | ¥45.41 | ¥45.84 | ¥44.20 | 8,095,974 | |
| ¥45.97 | -1.83 | -3.8% | ¥47.56 | ¥47.80 | ¥43.90 | 18,685,886 | |
| ¥47.80 | +0.84 | +1.8% | ¥46.95 | ¥47.84 | ¥46.39 | 6,542,171 | |
| ¥46.96 | -0.92 | -1.9% | ¥47.20 | ¥48.00 | ¥46.76 | 6,678,748 | |
| ¥47.88 | -1.03 | -2.1% | ¥48.91 | ¥48.91 | ¥47.16 | 8,948,423 | |
| ¥48.91 | -0.75 | -1.5% | ¥49.51 | ¥50.05 | ¥48.61 | 10,588,367 | |
| ¥49.66 | -1.59 | -3.1% | ¥51.00 | ¥51.39 | ¥48.64 | 10,457,437 | |
| ¥51.25 | -0.02 | 0.0% | ¥52.15 | ¥52.37 | ¥50.90 | 6,023,217 | |
| ¥51.27 | -0.34 | -0.7% | ¥52.00 | ¥52.50 | ¥51.03 | 6,203,064 | |
| ¥51.61 | -2.26 | -4.2% | ¥52.34 | ¥53.69 | ¥51.51 | 9,188,919 | |
| ¥53.87 | 0.00 | 0.0% | ¥53.76 | ¥55.15 | ¥53.31 | 12,381,834 | |
| ¥53.87 | +3.74 | +7.5% | ¥50.14 | ¥54.09 | ¥49.70 | 14,752,200 | |
| ¥50.13 | +0.47 | +0.9% | ¥49.70 | ¥51.56 | ¥48.38 | 13,371,904 | |
| ¥49.66 | -0.01 | 0.0% | ¥50.39 | ¥50.63 | ¥48.61 | 11,147,109 | |
| ¥49.67 | +1.48 | +3.1% | ¥48.40 | ¥53.39 | ¥47.72 | 16,831,871 | |
| ¥48.19 | -0.07 | -0.1% | ¥48.00 | ¥49.07 | ¥47.62 | 8,215,038 | |
| ¥48.26 | +0.44 | +0.9% | ¥48.78 | ¥49.12 | ¥46.42 | 14,775,035 | |
| ¥47.82 | -2.29 | -4.6% | ¥50.90 | ¥50.90 | ¥47.82 | 7,120,081 | |
| ¥50.11 | +1.31 | +2.7% | ¥48.80 | ¥50.97 | ¥48.61 | 9,737,456 | |
| ¥48.80 | -0.86 | -1.7% | ¥49.28 | ¥49.65 | ¥46.29 | 14,321,577 | |
| ¥49.66 | -1.53 | -3.0% | ¥51.44 | ¥51.86 | ¥48.88 | 9,105,247 | |
| ¥51.19 | -0.61 | -1.2% | ¥52.11 | ¥52.68 | ¥50.71 | 7,345,890 | |
| ¥51.80 | +1.22 | +2.4% | ¥50.50 | ¥52.18 | ¥49.60 | 7,568,986 | |
| ¥50.58 | +0.51 | +1.0% | ¥49.49 | ¥51.28 | ¥48.07 | 9,291,776 | |
| ¥50.07 | -1.99 | -3.8% | ¥53.00 | ¥54.48 | ¥49.28 | 12,543,170 | |
| ¥52.06 | -1.01 | -1.9% | ¥52.80 | ¥54.13 | ¥51.54 | 9,517,899 | |
| ¥53.07 | -1.25 | -2.3% | ¥54.10 | ¥54.92 | ¥53.02 | 6,636,408 | |
| ¥54.32 | -1.76 | -3.1% | ¥55.13 | ¥55.88 | ¥53.64 | 9,605,392 | |
| ¥56.08 | +0.90 | +1.6% | ¥55.01 | ¥58.27 | ¥55.00 | 11,358,277 | |
| ¥55.18 | -0.29 | -0.5% | ¥55.00 | ¥55.65 | ¥52.80 | 11,282,043 | |
| ¥55.47 | -2.93 | -5.0% | ¥58.05 | ¥58.48 | ¥55.16 | 12,392,749 | |
| ¥58.40 | +1.93 | +3.4% | ¥56.53 | ¥59.66 | ¥56.20 | 14,242,334 | |
| ¥56.47 | -0.33 | -0.6% | ¥56.83 | ¥58.64 | ¥56.29 | 9,636,905 | |
| ¥56.80 | -0.01 | 0.0% | ¥56.90 | ¥58.80 | ¥56.45 | 9,527,672 | |
| ¥56.81 | -1.69 | -2.9% | ¥57.92 | ¥58.70 | ¥56.79 | 7,923,318 | |
| ¥58.50 | +0.66 | +1.1% | ¥57.76 | ¥59.50 | ¥57.59 | 9,940,776 | |
| ¥57.84 | -1.15 | -1.9% | ¥58.81 | ¥59.15 | ¥57.55 | 12,733,295 | |
| ¥58.99 | +1.60 | +2.8% | ¥58.43 | ¥59.88 | ¥58.00 | 16,307,210 | |
| ¥57.39 | +0.38 | +0.7% | ¥57.01 | ¥59.39 | ¥56.66 | 15,984,092 | |
| ¥57.01 | +0.21 | +0.4% | ¥56.82 | ¥58.13 | ¥56.00 | 13,814,937 | |
| ¥56.80 | +0.99 | +1.8% | ¥55.61 | ¥57.17 | ¥55.00 | 14,939,956 | |
| ¥55.81 | -0.59 | -1.0% | ¥56.00 | ¥56.49 | ¥55.32 | 11,394,403 | |
| ¥56.40 | +3.60 | +6.8% | ¥53.00 | ¥56.64 | ¥52.80 | 21,286,207 | |
| ¥52.80 | -1.01 | -1.9% | ¥53.43 | ¥53.78 | ¥51.22 | 13,340,631 | |
| ¥53.81 | -0.87 | -1.6% | ¥54.66 | ¥55.00 | ¥53.02 | 10,550,047 | |
| ¥54.68 | +1.38 | +2.6% | ¥53.24 | ¥55.90 | ¥52.32 | 22,962,049 | |
| ¥53.30 | +4.04 | +8.2% | ¥49.27 | ¥53.88 | ¥48.84 | 23,526,980 | |
| ¥49.26 | -0.74 | -1.5% | ¥50.01 | ¥50.02 | ¥48.51 | 8,030,462 | |
| ¥50.00 | -0.61 | -1.2% | ¥51.20 | ¥51.20 | ¥49.54 | 8,125,100 | |
| ¥50.61 | +0.42 | +0.8% | ¥50.10 | ¥50.99 | ¥49.77 | 8,158,405 | |
| ¥50.19 | -1.21 | -2.4% | ¥51.40 | ¥51.86 | ¥50.00 | 9,964,308 | |
| ¥51.40 | -1.39 | -2.6% | ¥52.50 | ¥52.61 | ¥51.06 | 12,415,948 | |
| ¥52.79 | +2.94 | +5.9% | ¥49.64 | ¥54.22 | ¥49.00 | 31,225,920 | |
| ¥49.85 | -0.93 | -1.8% | ¥50.40 | ¥51.36 | ¥49.75 | 11,061,378 | |
| ¥50.78 | -0.07 | -0.1% | ¥50.60 | ¥50.97 | ¥49.60 | 12,365,517 | |
| ¥50.85 | -1.42 | -2.7% | ¥52.03 | ¥53.00 | ¥50.55 | 13,337,499 | |
| ¥52.27 | +3.11 | +6.3% | ¥49.40 | ¥52.88 | ¥48.63 | 22,060,604 | |
| ¥49.16 | -5.21 | -9.6% | ¥54.48 | ¥54.78 | ¥48.80 | 31,975,422 | |
| ¥54.37 | -1.15 | -2.1% | ¥54.00 | ¥55.26 | ¥52.74 | 22,440,928 | |
| ¥55.52 | +3.74 | +7.2% | ¥53.79 | ¥57.97 | ¥53.20 | 49,375,527 |
Splits
4 splits since 2013 · SZSE:300347 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-2 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- Shenzhen:300347
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Shenzhen
- Currency
- CNY
What changed lately
Latest news release · Sep 4, 2026
Hangzhou Tigermed Consulting: Tigermed and Veeda Lifesciences Forge Strategic Clinical Research for Global Drug Development
Latest deck · August 2026
H1 2026 Earnings Presentation
Earnings · 34 slides
Latest news
Hangzhou Tigermed Consulting: Tigermed and Veeda Lifesciences Forge Strategic Clinical Research for Global Drug Development
Sep 3, 2026
Closed ¥50.00 (-1.2%) on Sep 4, 2026
Tigermed Announces 2026 Interim Results
Aug 28, 2026
Closed ¥52.79 (+5.9%) on Aug 31, 2026
Tigermed Announces 2025 Annual Results
Mar 30, 2026
Closed ¥53.83 (+2.2%) on Mar 31, 2026
Hangzhou Tigermed Consulting Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 3 in the last 12 months · 13 in all · newest Sep 4, 2026 · oldest 2020
- Decks
- 16 decks · latest August 2026
Where Hangzhou Tigermed Consulting Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Shenzhen:300347 泰格医药 · Home listing · This page | Shenzhen | China | CNY |
| HKEX:3347 泰格醫藥 | HKEX | Hong Kong | HKD |
| LS Exchange:A2QALD | LS Exchange | Germany | EUR |
| OTC:HNGZY | OTC | United States | USD |
| gettex:5HZ1 | gettex | Germany | EUR |
| OTC:HTMDF | OTC | United States | USD |
| Dusseldorf:5HZ1 | Dusseldorf | Germany | EUR |
| Frankfurt:5HZ1 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2QALD | Lang & Schwarz | Germany | EUR |
| Munich:5HZ1 | Munich | Germany | EUR |
Valuation
EV/sales 4.2× against a median of 8.1×: 3rd lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥31.93B CNY
- P/E
- Loss
- EV/sales
- 4.2×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.7×
- Gross margin
- 26.2%
- Operating margin
- 10.1%
- Net margin
- −5.3%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347 | US$4.88B | US$4.79B | n/a | 4.2× | n/a | 1.7× | −5.3% | 0.1× | n/a |
| Bachem Holding AG Class B · SIX:BANB | US$6.80B | US$6.99B | 38.4× | 8.4× | 29.7× | 4.0× | 21.4% | 0.1× | n/a |
| 10x Genomics, Inc. · NASDAQ:TXG | US$6.29B | US$5.79B | n/a | 9.4× | n/a | 7.5× | −10.8% | 0.1× | 2.34 |
| Anthem Biosciences Limited · NSE:ANTHEM | US$5.78B | US$5.71B | 87.3× | 25.9× | 62.5× | 16.3× | 30.0% | 0.0× | n/a |
| Caris Life Sciences, Inc. · NASDAQ:CAI | US$4.97B | US$4.60B | 51.7× | 4.4× | 28.3× | 7.8× | 9.2% | 0.6× | 1.90 |
| DiaSorin S.p.A. · MIL:DIA | US$4.78B | US$4.60B | 28.0× | 3.5× | 11.7× | 2.8× | 13.0% | 0.0× | n/a |
| GRAIL, Inc. · NASDAQ:GRAL | US$4.46B | US$3.76B | n/a | 22.6× | n/a | 1.8× | −243.8% | 0.0× | 2.83 |
| SAI Life Sciences Ltd. · NSE:SAILIFE | US$4.13B | US$4.13B | 106× | 17.0× | 58.1× | 15.4× | 16.1% | 0.0× | n/a |
| BillionToOne, Inc. · NASDAQ:BLLN | US$3.83B | US$3.36B | 77.6× | 7.7× | 59.6× | 6.8× | 11.3% | 0.2× | 1.35 |
| CareDx, Inc. · NASDAQ:CDNA | US$3.68B | US$3.43B | 28.6× | 6.9× | n/a | 7.9× | 25.9% | 0.0× | 1.26 |
| Tecan Group AG · SIX:TECN | US$3.50B | US$3.49B | n/a | 3.3× | 34.0× | 2.6× | −12.5% | 0.2× | n/a |
| Median of the others | US$4.62B | US$4.36B | 51.7× | 8.1× | 34.0× | 7.1× | 12.2% | 0.1× | 1.90 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 60.07 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.73 · 2 analysts
- Revenue, year to Dec 2026
- 7.89B · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Chengcheng Yang | Senior Vice President, Chief Financial Officer |
| Hao Wu | Co-President |
| Zengyu Wen | Director, President |
| Bin Shan M.D. | Senior Vice President, Chief Information Officer |
| Jinlian Li | Senior Vice President, GM of China Innovative Drug Clinical Operations |
| Lihua Chen | Senior Vice President, GM of the Biometrics BU |
| Meng Song | Vice President, Chief Technology Officer |
| Shuang Mo | Vice President, Chief Compliance Officer |
| Sijia Hu | Senior Vice President, GM of SMO |
| Tianrong Ji | Senior Vice President, Chief Investment Officer |
| Xia Chen | Senior Vice President, Chief Medical Officer |
| Yunjie(Shelley) Gong | Senior Vice President, Chief Quality Officer |
| Zhenyu Dai | Senior Vice President, Head of BD |
| Xiaochun Cao | Co-founder, Director, Chair of the Board Executive Committee |
| Xiaoping Ye | Co-founder, Chairman |
Board
| Director | Role |
|---|---|
| Xiaoping Ye | Co-founder, Chairman |
| Xiaochun Cao | Co-founder, Director, Chair of the Board Executive Committee |
| Zengyu Wen | Director, President |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · Before open | −0.1% |
| Q2 2026 | Aug 28, 2026 · After close | +5.9% |
| Q1 2026 | Apr 28, 2026 · Before open | +2.7% |
| Q4 2025 | Mar 30, 2026 · Before open | −1.4% |
| Q3 2025 | Oct 28, 2025 · Before open | +0.3% |
| Q2 2025 | Aug 28, 2025 · Before open | −0.2% |
| Q1 2025 | Apr 29, 2025 | +1.0% |
| Q4 2024 | Mar 27, 2025 · Before open | +4.3% |
| Q3 2024 | Oct 29, 2024 · Before open | −3.9% |
| Q2 2024 | Aug 28, 2024 · Before open | +2.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · After close | +8.8% |
| Q4 2023 | Mar 28, 2024 · After close | +1.7% |
| Q3 2023 | Oct 27, 2023 · After close | +9.2% |
| Q2 2023 | Aug 25, 2023 · Before open | −3.2% |
| Q1 2023 | Apr 25, 2023 · Before open | −3.0% |
| Q4 2022 | Mar 28, 2023 · Before open | −0.9% |
| Q3 2022 | Oct 25, 2022 · After close | +12.4% |
| Q2 2022 | Aug 25, 2022 · Before open | +3.2% |
| Q1 2022 | Apr 26, 2022 · Before open | +0.9% |
| Q4 2021 | Mar 10, 2022 · Before open | +2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 34 slides | August 2026 |
| FY2025 Earnings Presentation | Earnings | 37 slides | March 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 31 slides | January 2026 |
| H1 2025 Earnings Presentation | Earnings | 33 slides | August 2025 |
| FY2024 Earnings Presentation | Earnings | 37 slides | March 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 28 slides | January 2025 |
| H1 2024 Earnings Presentation | Earnings | 32 slides | August 2024 |
| FY2023 Earnings Presentation | Earnings | 37 slides | March 2024 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 20 slides | January 2024 |
| H1 2023 Earnings Presentation | Earnings | 31 slides | August 2023 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2022 Earnings Presentation | Earnings | 35 slides | March 2023 |
| H1 2022 Earnings Presentation | Earnings | 31 slides | August 2022 |
| FY2021 Earnings Presentation | Earnings | 41 slides | March 2022 |
| H1 2021 Earnings Presentation | Earnings | 23 slides | August 2021 |
| FY2020 Earnings Presentation | Earnings | 26 slides | March 2021 |
| H1 2020 Earnings Presentation | Earnings | 22 slides | August 2020 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B | 3.19B | 2.80B | 2.30B | 1.69B | 1.17B |
| Cost of revenue | 4.96B | 4.36B | 4.54B | 4.28B | 2.94B | 1.68B | 1.50B | 1.31B | 962.6M | 727.9M |
| Gross profit | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B | 1.51B | 1.30B | 991.7M | 724.4M | 446.7M |
| Research and development | 257.6M | 238.4M | 261.6M | 234.6M | 211.8M | 156.6M | 124.0M | 88.0M | 49.7M | 41.9M |
| Selling, general and administrative | 322.2M | 736.8M | 650.2M | 630.1M | 547.5M | 390.6M | 349.6M | 314.2M | 236.5M | 228.4M |
| Operating income | 666.6M | 664.4M | 2.49B | 2.58B | 3.70B | 2.22B | 1.08B | 595.9M | 416.8M | 198.9M |
| Depreciation and amortization | 326.7M | 324.1M | 305.7M | 284.8M | 188.9M | 144.7M | 43.3M | 61.2M | 32.6M | 36.6M |
| EBITDA | 993.3M | 988.6M | 2.79B | 2.87B | 3.89B | 2.37B | 1.13B | 657.1M | 449.4M | 235.5M |
| Interest expense | 90.6M | 146.3M | 124.1M | 89.3M | 27.7M | 51.4M | 41.3M | 19.9M | 12.5M | 10.1M |
| Income before tax | 1.00B | 664.5M | 2.49B | 2.59B | 3.68B | 2.22B | 1.09B | 606.1M | 431.2M | 212.1M |
| Income tax | 216.6M | 338.6M | 313.7M | 292.9M | 189.7M | 113.8M | 99.3M | 99.1M | 55.3M | |
| Net income | 887.9M | 405.1M | 2.02B | 2.01B | 2.87B | 1.75B | 841.6M | 472.2M | 301.0M | 140.7M |
| Earnings per share, basic | 1.03 | 0.47 | 2.34 | 2.32 | 3.30 | 2.19 | 1.13 | 0.63 | 0.41 | 0.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.78B | 2.06B | 7.42B | 7.86B | 8.54B | 10.1B | 2.04B | 704.5M | 536.8M | 364.5M |
| Short-term investments | 59.5M | 74.9M | 42.1M | 24.9M | 29.2M | 26.0M | 68.8M | 587.4K | 76.0M | 174.5M |
| Receivables | 1.41B | 3.96B | 3.70B | 3.09B | 2.16B | 1.43B | 1.22B | 882.3M | 692.5M | 511.7M |
| Inventory | 41.5M | 32.0M | 23.4M | 22.2M | 6.10M | 4.72M | 1.21M | 518.9K | 14.0K | 59.9K |
| Current assets | 6.18B | 6.30B | 11.3B | 11.1B | 10.9B | 11.6B | 3.37B | 1.65B | 1.35B | 1.09B |
| Property, plant and equipment | 1.33B | 1.12B | 682.7M | 425.8M | 254.9M | 202.0M | 200.3M | |||
| Goodwill | 3.52B | 3.23B | 2.76B | 2.49B | 1.78B | 1.44B | 1.16B | 1.03B | 1.05B | 602.2M |
| Total assets | 28.4B | 28.7B | 29.7B | 27.4B | 23.7B | 19.5B | 7.57B | 4.68B | 3.58B | 2.39B |
| Accounts payable | 371.1M | 257.3M | 249.3M | 158.0M | 147.9M | 101.3M | 75.2M | 44.0M | 24.0M | 15.5M |
| Current liabilities | 2.84B | 3.66B | 4.14B | 3.73B | 2.41B | 1.14B | 1.81B | 1.26B | 733.2M | 435.8M |
| Long-term debt | 603.0M | 323.6M | 434.2M | 244.6M | 56.8M | 22.8M | 36.0M | 36.7M | ||
| Total debt | 2.63B | 2.83B | 2.58B | 899.2M | 279.0M | 1.04B | 712.8M | 259.9M | 190.9M | |
| Total liabilities | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B | 1.65B | 2.05B | 1.41B | 781.9M | 548.5M |
| Shareholders' equity | 21.0B | 20.7B | 21.0B | 19.6B | 18.1B | 16.1B | 4.23B | 2.84B | 2.49B | 1.63B |
| Shares outstanding | 861.0M | 863.0M | 864.9M | 865.5M | 871.0M | 799.0M | 744.8M | 749.5M | 740.1M | 703.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B | 998.7M | 527.6M | 522.2M | 315.0M | 191.9M |
| Capital spending | -214.4M | -356.6M | -313.8M | -448.6M | -368.6M | -156.5M | -102.9M | -91.7M | -46.0M | -61.7M |
| Free cash flow | 903.7M | 740.4M | 836.7M | 908.9M | 1.06B | 842.2M | 424.6M | 430.5M | 269.0M | 130.3M |
| Cash from investing | -4.74B | -1.53B | -2.79B | -2.78B | -2.37B | -638.2M | -366.5M | -846.4M | -530.0M | |
| Cash from financing | -1.70B | -7.81M | 809.3M | -163.1M | 9.34B | 1.43B | 10.0M | 702.3M | 485.7M | |
| Dividends paid | -343.7M | -642.2M | -589.9M | -432.5M | -261.7M | -271.3M | -174.6M | -126.6M | -62.3M | -59.1M |
| Share buybacks | -270.9M | -29.8M | -426.6M | -516.0M | -4.01M | -67.9M | -248.1M | |||
| Change in cash | -325.9M | -5.35B | -382.8M | -595.7M | -1.58B | 7.92B | 1.34B | 173.0M | 161.6M | 162.2M |
Cap table
Built by 6ix from Hangzhou Tigermed Consulting Co., Ltd. Class A’s releases
- Common shares
- 734,246,050
- Fully diluted
- 734,246,050
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 734,246,050 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 734,246,050 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bin Shan M.D. | Senior Vice President, Chief Information Officer · Since at least Nov 6, 2026 |
| Chengcheng Yang | Senior Vice President, Chief Financial Officer · Since at least Nov 6, 2026 |
| Hao Wu | Co-President · Since at least Mar 27, 2025 |
| Jinlian Li | Senior Vice President, GM of China Innovative Drug Clinical Operations · Since at least Nov 6, 2026 |
| Lihua Chen | Senior Vice President, GM of the Biometrics BU · Since at least Nov 6, 2026 |
| Meng Song | Vice President, Chief Technology Officer · Since at least Nov 6, 2026 |
| Shuang Mo | Vice President, Chief Compliance Officer · Since at least Nov 6, 2026 |
| Sijia Hu | Senior Vice President, GM of SMO · Since at least Nov 6, 2026 |
| Tianrong Ji | Senior Vice President, Chief Investment Officer · Since at least Nov 6, 2026 |
| Xia Chen | Senior Vice President, Chief Medical Officer · Since at least Nov 6, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Xiaochun Cao | Co-founder, Director, Chair of the Board Executive Committee · Since at least Aug 28, 2026 |
| Xiaoping Ye | Co-founder, Chairman · Since at least Aug 28, 2026 |
| Yunjie(Shelley) Gong | Senior Vice President, Chief Quality Officer · Since at least Nov 6, 2026 |
| Zengyu Wen | Director, President · Since at least Sep 4, 2026 |
| Zhenyu Dai | Senior Vice President, Head of BD · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Hangzhou Tigermed Consulting Co., Ltd.